Close Menu

NEW YORK – Biomarker test developer Biovica said today that it has inked an agreement with the SWOG Cancer Research Network to study the clinical benefit of its DiviTum immunoassay using blood samples from women with metastatic hormone receptor-positive breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.